Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Novel Coronavirus (COVID-19) Pipeline and Clinical Trials Analysis - May 2020 - ResearchAndMarkets.com


The "Pipeline and Clinical Trial Analysis - Coronavirus Disease 2019 (COVID-19) - May 2020" report has been added to ResearchAndMarkets.com's offering.

The global biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas.

Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.

Report Scope

Key Topics Covered

1. COVID-19 R&D Update

2. COVID-19 Clinical Trials

3. Impact of COVID-19 on Trial Timelines and Regulatory Approvals

4. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ragjit


These press releases may also interest you

at 17:00
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

at 16:45
Geron Corporation , a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...

at 16:33
A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual...



News published on and distributed by: